SG11201810794VA - Positive allosteric modulators of the muscarinic acetylcholine receptor m4 - Google Patents

Positive allosteric modulators of the muscarinic acetylcholine receptor m4

Info

Publication number
SG11201810794VA
SG11201810794VA SG11201810794VA SG11201810794VA SG11201810794VA SG 11201810794V A SG11201810794V A SG 11201810794VA SG 11201810794V A SG11201810794V A SG 11201810794VA SG 11201810794V A SG11201810794V A SG 11201810794VA SG 11201810794V A SG11201810794V A SG 11201810794VA
Authority
SG
Singapore
Prior art keywords
international
amine
avenue
compounds
nashville
Prior art date
Application number
SG11201810794VA
Other languages
English (en)
Inventor
Craig W Lindsley
P Jeffrey Conn
Darren W Engers
Sean Bollinger
James C Tarr
Paul Spearing
Julie L Engers
Madeline Long
Thomas M Bridges
Original Assignee
Univ Vanderbilt
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Family has litigation
First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=60675830&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=SG11201810794V(A) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.
Application filed by Univ Vanderbilt filed Critical Univ Vanderbilt
Publication of SG11201810794VA publication Critical patent/SG11201810794VA/en

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D495/00—Heterocyclic compounds containing in the condensed system at least one hetero ring having sulfur atoms as the only ring hetero atoms
    • C07D495/12—Heterocyclic compounds containing in the condensed system at least one hetero ring having sulfur atoms as the only ring hetero atoms in which the condensed system contains three hetero rings
    • C07D495/14—Ortho-condensed systems
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/50—Pyridazines; Hydrogenated pyridazines
    • A61K31/5025—Pyridazines; Hydrogenated pyridazines ortho- or peri-condensed with heterocyclic ring systems
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
    • A61K31/519—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim ortho- or peri-condensed with heterocyclic rings
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/04—Centrally acting analgesics, e.g. opioids
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/14—Drugs for disorders of the nervous system for treating abnormal movements, e.g. chorea, dyskinesia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/18—Antipsychotics, i.e. neuroleptics; Drugs for mania or schizophrenia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/20—Hypnotics; Sedatives
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/22—Anxiolytics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/24—Antidepressants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D491/00—Heterocyclic compounds containing in the condensed ring system both one or more rings having oxygen atoms as the only ring hetero atoms and one or more rings having nitrogen atoms as the only ring hetero atoms, not provided for by groups C07D451/00 - C07D459/00, C07D463/00, C07D477/00 or C07D489/00
    • C07D491/12—Heterocyclic compounds containing in the condensed ring system both one or more rings having oxygen atoms as the only ring hetero atoms and one or more rings having nitrogen atoms as the only ring hetero atoms, not provided for by groups C07D451/00 - C07D459/00, C07D463/00, C07D477/00 or C07D489/00 in which the condensed system contains three hetero rings
    • C07D491/14—Ortho-condensed systems
    • C07D491/147—Ortho-condensed systems the condensed system containing one ring with oxygen as ring hetero atom and two rings with nitrogen as ring hetero atom
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D493/00—Heterocyclic compounds containing oxygen atoms as the only ring hetero atoms in the condensed system
    • C07D493/12—Heterocyclic compounds containing oxygen atoms as the only ring hetero atoms in the condensed system in which the condensed system contains three hetero rings
    • C07D493/14—Ortho-condensed systems
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D495/00—Heterocyclic compounds containing in the condensed system at least one hetero ring having sulfur atoms as the only ring hetero atoms
    • C07D495/02—Heterocyclic compounds containing in the condensed system at least one hetero ring having sulfur atoms as the only ring hetero atoms in which the condensed system contains two hetero rings
    • C07D495/04—Ortho-condensed systems
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D519/00—Heterocyclic compounds containing more than one system of two or more relevant hetero rings condensed among themselves or condensed with a common carbocyclic ring system not provided for in groups C07D453/00 or C07D455/00

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • Biomedical Technology (AREA)
  • Neurology (AREA)
  • Neurosurgery (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Psychiatry (AREA)
  • Epidemiology (AREA)
  • Pain & Pain Management (AREA)
  • Hospice & Palliative Care (AREA)
  • Anesthesiology (AREA)
  • Psychology (AREA)
  • Heterocyclic Carbon Compounds Containing A Hetero Ring Having Oxygen Or Sulfur (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Nitrogen And Oxygen Or Sulfur-Condensed Heterocyclic Ring Systems (AREA)
  • Nitrogen Condensed Heterocyclic Rings (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Electrochromic Elements, Electrophoresis, Or Variable Reflection Or Absorption Elements (AREA)
  • Liquid Crystal Substances (AREA)
  • Control Of El Displays (AREA)
SG11201810794VA 2016-06-22 2017-06-22 Positive allosteric modulators of the muscarinic acetylcholine receptor m4 SG11201810794VA (en)

Applications Claiming Priority (4)

Application Number Priority Date Filing Date Title
US201662353447P 2016-06-22 2016-06-22
US201662418638P 2016-11-07 2016-11-07
US201762471281P 2017-03-14 2017-03-14
PCT/US2017/038711 WO2017223290A1 (en) 2016-06-22 2017-06-22 Positive allosteric modulators of the muscarinic acetylcholine receptor m4

Publications (1)

Publication Number Publication Date
SG11201810794VA true SG11201810794VA (en) 2019-01-30

Family

ID=60675830

Family Applications (1)

Application Number Title Priority Date Filing Date
SG11201810794VA SG11201810794VA (en) 2016-06-22 2017-06-22 Positive allosteric modulators of the muscarinic acetylcholine receptor m4

Country Status (31)

Country Link
US (4) US10239887B2 (zh)
EP (2) EP4186910A1 (zh)
JP (1) JP7038414B2 (zh)
KR (1) KR102474326B1 (zh)
CN (2) CN109310668B (zh)
AU (1) AU2017281228B2 (zh)
BR (1) BR112018003417B1 (zh)
CA (1) CA3026578A1 (zh)
CL (1) CL2018003669A1 (zh)
CO (1) CO2018013600A2 (zh)
CR (1) CR20180598A (zh)
DK (1) DK3474846T3 (zh)
DO (1) DOP2018000263A (zh)
EC (1) ECSP18094769A (zh)
ES (1) ES2936827T3 (zh)
FI (1) FI3474846T3 (zh)
GE (1) GEP20207167B (zh)
IL (1) IL263500B (zh)
JO (1) JOP20180114B1 (zh)
MA (1) MA45463A (zh)
MX (1) MX2018015878A (zh)
NI (1) NI201800141A (zh)
PE (1) PE20190446A1 (zh)
PH (1) PH12018502638A1 (zh)
RU (1) RU2750935C2 (zh)
SG (1) SG11201810794VA (zh)
SV (1) SV2018005800A (zh)
TN (1) TN2018000416A1 (zh)
UA (1) UA125874C2 (zh)
WO (1) WO2017223290A1 (zh)
ZA (1) ZA201808219B (zh)

Families Citing this family (17)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2017107089A1 (en) 2015-12-23 2017-06-29 Merck Sharp & Dohme Corp. 3- (1h-pyrazol-4-yl) pyridineallosteric modulators of the m4 muscarinic acetylcholine receptor
ES2789756T3 (es) 2015-12-23 2020-10-26 Merck Sharp & Dohme Moduladores alostéricos de 6,7-dihidro-5H-pirrolo[3,4-b]piridin-5-ona del receptor de acetilcolina muscarínico M4
TN2018000416A1 (en) 2016-06-22 2020-06-15 Univ Vanderbilt Positive allosteric modulators of the muscarinic acetylcholine receptor m4
EP3544961B1 (en) * 2016-11-07 2021-08-18 Vanderbilt University Positive allosteric modulators of the muscarinic acetylcholine receptor m4
JP7098167B2 (ja) 2016-11-07 2022-07-11 ヴァンダービルト ユニヴァーシティ ムスカリン性アセチルコリンレセプターｍ４のポジティブアロステリック調節因子
WO2018085808A1 (en) * 2016-11-07 2018-05-11 Vanderbilt University Positive allosteric modulators of the muscarinic acetylcholine receptor m4
WO2018112840A1 (en) 2016-12-22 2018-06-28 Merck Sharp & Dohme Corp. 6, 5-fused heteroaryl piperidine ether allosteric modulators of the m4 muscarinic acetylcholine receptor
WO2018112842A1 (en) 2016-12-22 2018-06-28 Merck Sharp & Dohme Corp. 6,6-fused heteroaryl piperidine ether allosteric modulators of m4 muscarinic acetylcholine receptor
WO2018112843A1 (en) 2016-12-22 2018-06-28 Merck Sharp & Dohme Corp. Heteroaryl piperidine ether allosteric modulators of the m4 muscarinic acetylcholine receptor
WO2019000237A1 (en) 2017-06-27 2019-01-03 Merck Sharp & Dohme Corp. ALLOSTERIC MODULATORS OF 3- (1H-PYRAZOL-4-YL) PYRIDINE FROM THE M4 ACETYLCHOLINE MUSCARINIC RECEPTOR
WO2019000236A1 (en) 2017-06-27 2019-01-03 Merck Sharp & Dohme Corp. ALLOSTERIC MODULATORS OF 3- (1H-PYRAZOL-4-YL) PYRIDINE FROM THE M4 ACETYLCHOLINE MUSCARINIC RECEPTOR
WO2019000238A1 (en) 2017-06-27 2019-01-03 Merck Sharp & Dohme Corp. 5- (PYRIDIN-3-YL) OXAZOLE ALLOSTERIC MODULATORS OF M4 ACETYLCHOLINE MUSCARINIC RECEPTOR
TW201930311A (zh) 2017-12-05 2019-08-01 泛德比爾特大學 蕈毒鹼型乙醯膽鹼受體m4之正向別構調節劑
MA51036A (fr) 2017-12-05 2021-03-17 Univ Vanderbilt Modulateurs allostériques positifs du récepteur muscarinique de l'acétylcholine m4
CN110950774B (zh) * 2019-11-04 2021-04-13 北京大学 蛋白质定量标记试剂及其制备方法与应用
WO2022226078A1 (en) * 2021-04-20 2022-10-27 The Regents Of The University Of California Therapy for alcohol-related liver disease
EP4447953A1 (en) 2021-12-13 2024-10-23 Sage Therapeutics, Inc. Combination of muscarinic receptor positive modulators and nmda positive allosteric modulators

Family Cites Families (42)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5594001A (en) 1993-04-08 1997-01-14 The Dupont Merck Pharmaceutical Company Polycyclic systems, and derivatives thereof, as neurotransmitter release enhancers useful in the treatment of cognitive disorders
IL112248A0 (en) 1994-01-25 1995-03-30 Warner Lambert Co Tricyclic heteroaromatic compounds and pharmaceutical compositions containing them
US5654307A (en) * 1994-01-25 1997-08-05 Warner-Lambert Company Bicyclic compounds capable of inhibiting tyrosine kinases of the epidermal growth factor receptor family
AU2001231154A1 (en) * 2000-01-24 2001-07-31 Adherex Technologies Inc. Peptidomimetic modulators of cell adhesion
US6608053B2 (en) * 2000-04-27 2003-08-19 Yamanouchi Pharmaceutical Co., Ltd. Fused heteroaryl derivatives
AU7905001A (en) * 2000-07-27 2002-02-13 Pharmacia Corp Epoxy-steroidal aldosterone antagonist and beta-adrenergic antagonist combination therapy for treatment of congestive heart failure
US7291733B2 (en) * 2003-10-10 2007-11-06 Boehringer Ingelheim Pharmaceuticals, Inc. Substituted tricyclic heterocycles and their uses
DE602004022318D1 (de) * 2003-10-14 2009-09-10 Supergen Inc Proteinkinaseinhibitoren
US20090099165A1 (en) * 2003-10-14 2009-04-16 Arizona Board Of Regents On Behalf Of The University Of Arizona Protein Kinase Inhibitors
PE20060526A1 (es) 2004-06-15 2006-07-13 Schering Corp Compuestos triciclicos como antagonistas de mglur1
EP1619196A1 (de) 2004-07-23 2006-01-25 Curacyte Discovery GmbH Substituierte Pyrido[3',2':4,5]thieno[3,2-d]pyrimidine und Pyrido[3',2':4,5]furo[3,2-d]-pyrimidine zur Verwendung als Inhibitoren der PDA-4 und/oder TNF-alpha Freisetzung
WO2006010567A1 (de) 2004-07-23 2006-02-02 Curacyte Discovery Gmbh INHIBITOREN DER PHOSPHODIESTERASE 4 UND TNFα-FREISETZUNG
CN100577666C (zh) 2004-10-25 2010-01-06 伊莱利利公司 作为m4毒蕈碱性受体的变构增效剂的噻吩并吡啶类
ES2259891B1 (es) 2004-11-30 2007-11-01 Laboratorios Almirall S.A. Nuevos derivados de piridotienopirimidina.
ES2259892B1 (es) 2004-11-30 2007-11-01 Laboratorios Almirall S.A. Nuevos derivados de piridotienopirimidina.
WO2006138418A2 (en) * 2005-06-14 2006-12-28 President And Fellows Of Harvard College Improvement of cognitive performance with sirtuin activators
AR059901A1 (es) 2006-03-20 2008-05-07 Bayer Pharmaceuticals Corp Compuestos de tetrahidropiridotienopirimidina utiles para tratar o prevenir trastornos proliferativos celulares.
US20080021063A1 (en) * 2006-07-18 2008-01-24 Kazantsev Aleksey G Compositions and methods for modulating sirtuin activity
US7547781B2 (en) * 2006-09-11 2009-06-16 Curis, Inc. Quinazoline based EGFR inhibitors containing a zinc binding moiety
EP2476679B1 (en) * 2006-12-29 2015-10-14 Rigel Pharmaceuticals, Inc. Substituted triazoles useful as AXL inhibitors
CA2684659C (en) * 2007-04-20 2015-11-24 Glaxo Group Limited Tricyclic nitrogen containing compounds as antibacterial agents
US20090105240A1 (en) 2007-10-17 2009-04-23 Tomas Mustelin Methods for treating leukemia and myelodysplastic syndrome, and methods for identifying agents for treating same
WO2009151569A2 (en) * 2008-06-09 2009-12-17 Combinatorx, Incorporated Beta adrenergic receptor agonists for the treatment of b-cell proliferative disorders
NZ597983A (en) 2009-08-20 2014-05-30 Karus Therapeutics Ltd Tricyclic heterocyclic compounds as phosphoinositide 3-kinase inhibitors
US20110178107A1 (en) 2010-01-20 2011-07-21 Taigen Biotechnology Co., Ltd. Hcv protease inhibitors
RU2451686C1 (ru) * 2010-12-27 2012-05-27 Александр Васильевич Иващенко ЗАМЕЩЕННЫЕ ГИДРИРОВАННЫЕ ТИЕНО-ПИРРОЛО [3,2-c] ПИРИДИНЫ, ЛИГАНДЫ, ФАРМАЦЕВТИЧЕСКАЯ КОМПОЗИЦИЯ И СПОСОБ ИХ ПРИМЕНЕНИЯ
WO2012131297A1 (en) 2011-03-28 2012-10-04 Jonathan Bayldon Baell Pyrido [3',2' :4,5] thieno [3, 2-d] pyrimidin- 4 - ylamine derivatives and their therapeutical use
US9056876B2 (en) 2011-09-16 2015-06-16 Vanderbilt University Substituted 1H-pyrazolo[3′,4′,4,5]thieno[2,3-b]pyridin-3-amine analogs as positive allosteric modulators of the muscarinic acetylcholine receptor M4
US20130116241A1 (en) 2011-11-09 2013-05-09 Abbvie Inc. Novel inhibitor compounds of phosphodiesterase type 10a
KR102097343B1 (ko) 2011-12-21 2020-04-07 더 리전츠 오브 더 유니버시티 오브 콜로라도, 어 바디 코퍼레이트 RAL GTPases를 타겟으로 하는 항암용 화합물 및 이의 사용방법
US8697888B2 (en) * 2012-01-06 2014-04-15 Vanderbilt University Substituted (1-(methylsulfonyl)azetidin-3-yl)(heterocycloalkyl)methanone analogs as antagonists of muscarinic acetylcholine M1 receptors
WO2013126856A1 (en) 2012-02-23 2013-08-29 Vanderbilt University Substituted 5-aminothieno[2,3-c]pyridazine-6-carboxamide analogs as positive allosteric modulators of the muscarinic acetylcholine receptor m4
US9085586B2 (en) 2012-07-11 2015-07-21 Nimbus Iris, Inc. IRAK inhibitors and uses thereof
US9056875B2 (en) * 2012-08-31 2015-06-16 Vanderbilt University Substituted pyrazolo[3′,4′:4,5]thieno[2,3-C]pyridazin-3-amine analogs as positive allosteric modulators of the muscarinic acetylcholine receptor M4
WO2015027204A1 (en) 2013-08-23 2015-02-26 Vanderbilt University Substituted thieno[2,3-b]pyridine-2-carboxamide analogs as positive allosteric modulators of the muscarinic acetylcholine receptor m4
EP3036233A1 (en) 2013-08-23 2016-06-29 Vanderbilt University Substituted thieno[2,3-c]pyridazine-6-carboxamide analogs as positive allosteric modulators of the muscarinic acetylcholine receptor m4
US9981920B2 (en) * 2014-06-26 2018-05-29 Rodin Therapeutics, Inc. Inhibitors of histone deacetylase
TN2018000416A1 (en) * 2016-06-22 2020-06-15 Univ Vanderbilt Positive allosteric modulators of the muscarinic acetylcholine receptor m4
EP3544961B1 (en) 2016-11-07 2021-08-18 Vanderbilt University Positive allosteric modulators of the muscarinic acetylcholine receptor m4
WO2018085808A1 (en) 2016-11-07 2018-05-11 Vanderbilt University Positive allosteric modulators of the muscarinic acetylcholine receptor m4
JP7098167B2 (ja) 2016-11-07 2022-07-11 ヴァンダービルト ユニヴァーシティ ムスカリン性アセチルコリンレセプターｍ４のポジティブアロステリック調節因子
MA51036A (fr) * 2017-12-05 2021-03-17 Univ Vanderbilt Modulateurs allostériques positifs du récepteur muscarinique de l'acétylcholine m4

Also Published As

Publication number Publication date
PE20190446A1 (es) 2019-03-29
IL263500A (en) 2019-01-31
CR20180598A (es) 2019-11-20
CL2018003669A1 (es) 2019-02-01
AU2017281228B2 (en) 2021-02-18
JOP20180114B1 (ar) 2022-09-15
GEP20207167B (en) 2020-10-12
CN116178391A (zh) 2023-05-30
EP4186910A1 (en) 2023-05-31
JP2019523233A (ja) 2019-08-22
UA125874C2 (uk) 2022-06-29
US20190161498A1 (en) 2019-05-30
US20230348490A1 (en) 2023-11-02
EP3474846B1 (en) 2022-11-30
ECSP18094769A (es) 2019-01-31
CN109310668B (zh) 2023-01-24
ZA201808219B (en) 2020-05-27
BR112018003417A2 (zh) 2018-10-02
JP7038414B2 (ja) 2022-03-18
SV2018005800A (es) 2019-02-13
WO2017223290A1 (en) 2017-12-28
DK3474846T3 (da) 2023-02-06
BR112018003417B1 (pt) 2023-10-24
US20170369505A1 (en) 2017-12-28
EP3474846A1 (en) 2019-05-01
KR20190018645A (ko) 2019-02-25
EP3474846A4 (en) 2019-12-04
MA45463A (fr) 2019-05-01
CN109310668A (zh) 2019-02-05
DOP2018000263A (es) 2019-03-31
US11142532B2 (en) 2021-10-12
NI201800141A (es) 2020-07-22
ES2936827T3 (es) 2023-03-22
IL263500B (en) 2021-09-30
FI3474846T3 (fi) 2023-02-16
US10239887B2 (en) 2019-03-26
KR102474326B1 (ko) 2022-12-05
US20230014109A1 (en) 2023-01-19
JOP20180114A1 (ar) 2019-01-30
MX2018015878A (es) 2019-05-27
CO2018013600A2 (es) 2018-12-28
PH12018502638A1 (en) 2019-10-21
RU2750935C2 (ru) 2021-07-06
RU2018142987A3 (zh) 2020-07-24
RU2018142987A (ru) 2020-07-22
TN2018000416A1 (en) 2020-06-15
CA3026578A1 (en) 2017-12-28
AU2017281228A1 (en) 2018-12-20

Similar Documents

Publication Publication Date Title
SG11201810794VA (en) Positive allosteric modulators of the muscarinic acetylcholine receptor m4
SG11201807252QA (en) Anti-lag-3 antibodies
SG11201807301SA (en) Spiro-condensed pyrrolidine derivatives as deubiquitylating enzymes (dub) inhibitors
SG11201903182XA (en) 6,7,8,9-tetrahydro-3h-pyrazolo[4,3-f]isoquinoline derivatives useful in the treatment of cancer
SG11201808220VA (en) Allosteric modulators of nicotinic acetylcholine receptors
SG11201808622SA (en) Chimeric receptors to flt3 and methods of use thereof
SG11201900163PA (en) Macrocycle kinase inhibitors
SG11201809857TA (en) Anti-CTLA-4 Antibodies
SG11201901628XA (en) Methods and compositions for spinal cord cells
SG11201808708RA (en) Heterocyclic amides useful as protein modulators
SG11201408186TA (en) Pyridinone and pyridazinone derivatives
SG11201901959YA (en) Modified stem cell memory t cells, methods of making and methods of using same
SG11201408821SA (en) Selective pi3k delta inhibitors
SG11201908325PA (en) Process for the preparation of glucuronide drug-linkers and intermediates thereof
SG11201407682TA (en) Heteroaryl-ketone fused azadecalin glucocorticoid receptor modulators
SG11201909807TA (en) Methods of manufacturing of niraparib
SG11201806400XA (en) Replicative transposon system
SG11201810965YA (en) 1h-pyrazolo[4,3-b]pyridines as pde1 inhibitors
SG11201901438VA (en) Solid forms of cenicriviroc mesylate and processes of making solid forms of cenicriviroc mesylate
SG11201903602RA (en) Use of beta-catenin as a biomarker for treating cancers using anti-dkk-1 antibody
SG11201811671XA (en) Prins reaction and intermediates useful in the synthesis of halichondrin macrolides and analogs thereof
SG11201809531SA (en) BINDING MOLECULES SPECIFIC FOR FCγGAMMA RIIA AND USES THEREOF
SG11201809560QA (en) Enhancer of zeste homolog 2 inhibitors
SG11201906767XA (en) Estrogen receptor modulators
SG11201906359SA (en) Compositions and methods for maturation of oocytes in vitro